Compare ICHR & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | PAHC |
|---|---|---|
| Founded | 1999 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2016 | 2014 |
| Metric | ICHR | PAHC |
|---|---|---|
| Price | $30.93 | $33.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $83.25 | $47.00 |
| AVG Volume (30 Days) | ★ 1.0M | 188.4K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 104.20 |
| EPS | 0.53 | ★ 0.72 |
| Revenue | ★ $947,652,000.00 | $833,350,000.00 |
| Revenue This Year | $30.37 | $3.91 |
| Revenue Next Year | $32.01 | $3.48 |
| P/E Ratio | $62.98 | ★ $54.76 |
| Revenue Growth | ★ 11.61 | 4.12 |
| 52 Week Low | $14.07 | $28.25 |
| 52 Week High | $113.58 | $60.08 |
| Indicator | ICHR | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 35.15 |
| Support Level | $27.03 | $32.97 |
| Resistance Level | $53.95 | $34.67 |
| Average True Range (ATR) | 2.69 | 1.60 |
| MACD | -0.81 | -0.54 |
| Stochastic Oscillator | 17.02 | 1.94 |
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.